Objective: The purpose of this study was to determine if: 1) insulin-like growth factor binding protein-1 (IGFBP-1) in amniotic fluid (AF) exhibited proteolytic cleavage in cases of intra-amniotic inflammation; and 2) if the matrix metalloproteinases (MMP-3, MMP-8, MMP-9) in AF are associated with the degradation of IGFBP-1 in AF. Methods: AF samples (ns20) were obtained from preterm gestations with and without intra-amniotic inflammation. The form of IGFBP-1 in AF was assessed by Western blot analysis and AF MMP-8 concentration was measured by ELISA. Densitometric analysis of Western blot was performed and the fragmented/intact IGFBP-1 ratio was calculated. Proteolysis of AF IGFBP-1 by MMPs was evaluated by incubating AF with exogenous human MMP-3, MMP-8 or MMP-9, and by incubating recombinant human IGFBP-1 in AF with and without inflammation. Results: 1) IGFBP-1 was present in AF without inflammation as an intact form; however, the fragmented form was dominant in AF with inflammation; 2) the ratio of fragmented/intact IGFBP-1 was significantly higher in AF with inflammation than in AF without inflammation; 3) a higher ratio of fragmented/intact IGFBP-1 was associated with a higher concentration of MMP-8; 4) in-vitro proteolysis experiments showed that AF IGFBP-1 was degraded by exogenous human MMP-3, MMP-8 and MMP-9; 5) recombinant human IGFBP-1 was fragmented in AF with inflammation, but not in AF without inflammation.
Introduction
Intra-amniotic inflammation/infection is a risk factor for impending preterm delivery and adverse pregnancy outcome w2, 11, 14, 28, 31x. Matrix metalloproteinases (MMPs), proteolytic enzymes derived at the site of inflammation, play a central role in the mechanisms responsible for preterm labor or premature rupture of membranes resulting in preterm birth. The amniotic fluid (AF) concentrations of some MMPs have been reported to be significantly elevated in the presence of intra-amniotic infection/inflammation w3, 5, 23, 26x.
During pregnancy, the insulin-like growth factor binding protein-1 (IGFBP-1) is produced in decidua and exists in high concentration in AF and maternal serum w22, 29x. Insulin-like growth factor binding proteins (IGFBPs) have high affinity to insulin-like growth factors (IGFs) and antagonize the binding of IGFs to their receptors. Indeed, IGFBP-1 is known to be involved in placental development by modulating the action of IGF w8, 10, 12x. Protease-mediated fragmentation of IGFBPs results in release of IGFs from IGF/IGFBP complex and allows free IGFs to bind to and activate IGF receptors w12x. Several studies indicated that MMPs act as IGFBP protease and proteolytic cleavage of IGFBPs by specific MMPs has been reported w7, 8, 10, 17, 20x.
The purpose of this study was to investigate if the cleavage of IGFBP-1 by MMPs (MMP-3, MMP-8 and MMP-9) would occur in intra-amniotic inflammation, and if the form of IGFBP-1 would change from intact to fragmented.
Materials and methods

Amniotic fluid
The form of IGFBP-1 was assessed by Western blot analysis in 20 AF samples obtained from preterm gestations. Characteristics of the study cases are described in Table 1 . AF samples were collected by transabdominal amniocentesis or at the time of cesarean section and were centrifuged and stored in poly- propylene tubes at -708C until studied. AF was collected after written informed consent was obtained. The Institutional Review Board of Seoul National University approved the collection of biological materials and data from these patients for research purposes. The Seoul National University has a Federal Wide Assurance with the Office for Human Research Protections of the Department of Health and Human Services of the United States. AF inflammation was defined as an elevated AF MMP-8 concentration ()23 ng/ml), as previously reported w27x. MMP-8 concentration was measured with a commercially available enzyme-linked immunosorbent assay (Amersham Pharmacia Biotech, Inc., Bucks, UK). The sensitivity of the test was 0.3 ng/mL. Intra-and inter-assay coefficients of variation were 3.1% and 9.5%, respectively.
Western blot analysis
1-2 mL of human AF was diluted with sodium dodecyl sulfate (SDS)-loading buffer and boiled for 10 min and subjected to SDS-PAGE using 13.5% gels. Proteins were then transferred to a polyvinylidene difluoride (PVDF) membrane (Millipore, Bedford, MA) at 30 V for 1 h. Non-specific binding was blocked overnight with a 5% milk protein in 0.1% TBS-T (0.1% wvol/volx Tween 20 in Tris-buffer saline) at 48C. After washing with 0.1% TBS-T, the membrane was incubated with 1:1000 dilution of rabbit antihuman IGFBP-1 polyclonal antibody (Upstate, Lake Placid, NY) diluted in the blocker at room temperature for 1.5 h. The membrane was washed and incubated with 1:5000 dilution of alkaline phosphatase-labeled goat anti-rabbit antibody (Zymed Laboratories, San Francisco, CA) diluted in the 0.1% TBS-T at room temperature for 1 h. A BCIP/NBT tablet (Sigma, St Louis, MO) diluted in distilled water was used for development.
AF IGFBP-1 proteolysis by MMPs
The ability of human MMPs to degrade AF IGFBP-1 was evaluated by incubating 2 mL of AF with exogenous human MMP-3, MMP-8 or MMP-9 (6 pmol for each MMP; Calbiochem, Figure 2 Densitometric analysis of amniotic fluid (AF) IGFBP-1 protein; the ratio of fragmented/intact IGFBP-1 was significantly higher in AF with inflammation than that in AF without inflammation (for total fragment: median 0.41 wrange, 0.13-0.69x vs. median 3.0 wrange, 1.17-8.77x; for 21 kDa fragment: median 0.33 wrange, 0.13-0.49x vs. median 1.57 wrange, 0.73-3.75x; for 17 kDa fragment: median 0.05 wrange, 0.00-0.15x vs. median 0.60 wrange, 0.21-3.35x; for 12 kDa fragment: median 0.06 wrange, 0.00-0.15x vs. median 0.34 wrange, 0.17-1.67x. P-0.001, respectively). F/I ratio, IGFBP-1 protein fragmented/intact form ratio by densitometric analysis.
Darmstadt, Germany) in a solution of 50 mM Tris (pH 7.5) containing 150 mM NaCl, 10 mM CaCl 2 , and 0.05% Triton (final volume 20 mL). To activate proenzyme, 1 mM p-aminophenylmercuric acetate (APMA) solution (Calbiochem, Darmstadt, Germany) was used. The solution was incubated at 378C for 12-24 h, and the reaction was terminated by adding SDS-PAGE sample buffer and boiling the mixture.
Recombinant human IGFBP-1 (rhIGFBP-1) proteolysis in amniotic fluid
rhIGFBP-1 (100 ng; R&D systems, Minneapolis, MN) was incubated in 10 mL of AF with or without inflammation. The solution was incubated at 378C for 6-12 h, and the reaction was stopped by adding reducing sample buffer and boiling the mixture. A time course of IGFBP-1 degradation in AF was evaluated by analyzing the aliquots with Western blot.
Densitometric analysis
Densitometric analysis of the results of Western blot (scanned images of membranes) was performed with the TINA 2.0 software program (Raytest, Staubenhardt). Ratio of proteolytic fragment to intact IGFBP-1 was calculated. The fragmented/intact IGFBP-1 ratio in AF between groups with and without inflammation were compared with the Mann-Whitney U-test. A P-value of -0.05 was considered significant.
Results
Difference in the form of IGFBP-1 in AF with and without inflammation
Results of Western blot analysis for IGFBP-1 in AF showed that IGFBP-1 was present in AF without inflam- mation as an intact form of 30 kDa (Figure 1) . However, the intact form of IGFBP-1 decreased and fragments were seen at 21, 17 and 12 kDa on the result of immunoblot for AF with inflammation. A total of 20 cases were analyzed, and the ratio of fragmented/intact IGFBP-1 was significantly higher in AF with inflammation than in AF without inflammation (Figure 2) . Figure 3 shows that a higher ratio of fragmented/intact IGFBP-1 was associated with a higher concentration of AF MMP-8. Fragment detection decreased in AF without Figure 4 rhIGFBP-1 proteolysis in amniotic fluid (AF) without (A) or with (B) inflammation; 100 ng of rhIGFBP-1 was incubated in 10 mL of AF at 378C. There was no change in the form of rhlGFBP-1 in AF without inflammation (A). However, intact rhlGFBP-1 (30 kDa) was gradually degraded in AF with inflammation and 12 kDa fragment increased (B). Independent experiments were done on four cases of AF and representative cases were shown. inflammation ( Figure 3A, lanes 1 and 2) . As AF MMP-8 concentration increased, fragments of IGFBP-1 increased and intact IGFBP-1 decreased. At higher MMP-8 concentrations, intact IGFBP-1 almost disappeared ( Figure 3A, lanes 5-7) . Figure 4 shows the change of exogenous rhIGFBP-1 in AF with and without inflammation. Experiments were done on four cases of AF. MMP-8 concentrations of AF with inflammation were 415.2 and 2199.9 ng/mL, and those of control AF were -0.3 ng/mL. After 12 h of incubation, intact rhIGFBP-1 was gradually degraded in AF with inflammation and 12 kDa fragment increased. However, there was no change in the form of rhIGFBP-1 in AF without inflammation.
The relationship between the change of IGFBP-1 and the degree of AF inflammation measured by AF MMP-8 concentration
rhIGFBP-1 degradation in AF with inflammation
Time-course of IGFBP-1 proteolysis by exogenous MMP-3, MMP-8 and MMP-9
Figure 5 demonstrates that AF IGFBP-1 was degraded by exogenous human MMP-3, MMP-8 and MMP-9 in a time-dependent manner. MMP-3 cleaved intact IGFBP-1 in AF into three fragments of 23, 21 and 12 kDa. MMP-9 degraded into 21, 17 and 12 kDa fragments. MMP-8 proteolyzed AF IGFBP-1 into four fragments of 21, 17, 14 and 12 kDa. However, there was no change in the form of AF IGFBP-1 in the control AF.
Comment
Principal findings of this study 1) IGFBP-1 was present as an intact form in AF without inflammation. However, a fragmented form of IGFBP-1 was dominant in AF with inflammation; 2) the ratio of fragmented/intact IGFBP-1 was significantly higher in AF with inflammation than in AF without inflammation; 3) a higher ratio of fragmented/intact IGFBP-1 was associated with a higher degree of inflammation; 4) rhIGFBP-1 was fragmented in AF with inflammation, but not in AF without inflammation; and 5) in vitro experiments showed that an intact form of IGFBP-1 in AF was degraded by exogenous human MMP-3, MMP-8 and MMP-9 in a time-dependent manner.
Degradation of IGFBP-1 in AF with inflammation
IGFBP-1 originates from decidua and exists in a high concentration during pregnancy w8, 10, 12, 19x. Substantial evidence indicates that IGFBP-1 is likely to play an important role in human pregnancy w12x, and in particular, it is thought to be associated with placental development w10, 17, 19, 22x. Elevated decidual concentration of IGFBP-1 is known to inhibit invasion of trophoblast w19, 29x. A recent study indicated that cleavage of IGFBP-1 by MMP-3 and MMP-9 might increase IGF bioavailability and control placental development in early pregnancy w10x. Women with preeclampsia have a higher serum IGFBP-1 concentration compared to those with normal pregnancies w4, 16, 18x. The IGFBP system is also thought to be involved in fetal growth w6, 9, 30x. However, the role of IGFBP system in intra-uterine inflammation during pregnancy has not been discussed. This study demonstrated that IGFBP-1 in AF was cleaved by MMPs produced in an inflammatory condition. Our data suggest a possible role of AF IGFBP-1 in the pathologic process of AF inflammation leading to preterm birth.
IGFBP-1 as a substrate of MMP-8
This study reveals that MMP-3, MMP-8 and MMP-9 cause proteolytic degradation of IGFBP-1 in AF. Several studies have reported that IGFBPs play a role of a substrate for MMPs w7, 10, 13, 17, 21, 22, 24, 25x. Proteolysis of IGFBPs is the mechanism by which MMPs control the bioactivity of the IGF system. IGFBP-1 has been reported as a substrate for MMP-2, MMP-3, MMP-7, MMP-9, and MMP-11 w7, 10, 21, 25x. The proteolysis of IGFBP-1 by MMP-3 and MMP-9 was also demonstrated in the present study. However, to our knowledge, this is the first study showing that MMP-8 is responsible for the proteolysis of IGFBP-1. This novel finding suggests that MMP-8 could regulate bioavailability of the IGF system in an inflammatory condition by means of proteolysis of IGFBP-1.
AF IGFBP-1 fragment as a possible biomarker of preterm birth
Our data showed that a specific proteolytic fragment of IGFBP-1 might be a novel biomarker of intra-amniotic inflammation leading to preterm birth. Indeed, a proteomics-based study has found 11 kDa proteolytic fragment of IGFBP-1 in AF and pooled maternal serum of patients with intra-amniotic infection w15x. Our study proved the mechanism for the production of fragments of IGFBP-1, which was MMPs-related proteolysis in AF with inflammation. Moreover, our data showed that not only the 11 kDa fragment but other fragments (21, 17 and 14 kDa) should be considered.
Intra-uterine inflammation/infection, as well as other pathologic mechanisms (e.g., activation of the maternal or fetal HPA axis, systemic inflammation, decidual hemorrhage, and pathologic distension of the uterus) can result in preterm birth w1x. Present data only suggest a proteolytic fragment of IGFBP-1 as a marker of AF inflammation/infection. However, proteolysis of IGFBP-1 may occur to regulate IGF system of the fetal/maternal surface in the absence of intra-amniotic inflammation. Coppock et al. w10x demonstrated that decidual cells produced protease as well as IGFBP-1 in the first trimester, and cleavage of IGFBP-1 by MMP-3 and MMP-9 occurred to control placental development. Moreover, ''decidual activation'' is considered as a common biochemical pathway involving initiating parturition. Therefore, future research is needed to evaluate if a specific proteolytic fragment of IGFBP-1 could be a biomarker of preterm birth resulting from other mechanisms of disease.
